MAP4K4-IN-3

SKU: orb1309449

Description

MAP4K4-IN-3 (Compound 17) is a serine/threonine kinase inhibitor with potential as an antidiabetic agent. It is a research tool for studying MAP4K4's role in insulin resistance and metabolic disease, applicable in both cellular and animal models.

Research Area

Signal Transduction

Key Properties

• CAS Number: 1811510-58-3
• MW: 297.74
• Purity: 99.50% (May vary between batches)
• Formula: C₁₅H₁₂ClN₅
• SMILES: Nc1ncc(cn1)-c1cnc(N)c(c1)-c1ccc(Cl)cc1
• Target: MAPK
• Solubility: DMSO:8 mg/mL (26.87 mM)

Bioactivity

• Target IC50:
  MAP4K4:14.9 nM
• In Vivo:
  Administering MAP4K4-IN-3 (Compound 2; 25 mg/kg, b.i.d.) orally to telemetered rats over a period of five days induces several adverse reactions. Cardiovascular measurements reveal a significant increase in maximal heart rate by 25 beats per minute (bpm) compared to control groups upon treatment with MAP4K4-IN-3. Additionally, there are noticeable declines in body weight (7%) and an increase in body temperature (0.4°C) against control values throughout the study.
  Read more...
• In Vitro:
  MAP4K4-IN-3, Antidiabetic agent.MAP4K4-IN-3 is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Compound 17, MAPK Kinase Kinase Kinase, MAP4K, MAP4K4, MAP4K4 IN 3, MAP4K4IN3, MAP-4K4-IN-3, MAP4K4-IN-3, Inhibitor, inhibit

Compound Identifiers

PubChem CID

127036775